TG Therapeutics TGTX Q2 2026: Revenue Surges but EPS Misses by 89%
As seen on the 24/7 Wall St. homepage on August 3, 2026.
BRIUMVI's commercial muscle delivered 70% revenue growth and pushed TG Therapeutics to raise full-year guidance to $950M, but a cash-incinerating R&D ramp to develop subcutaneous formulations crushed earnings per share to $0.05, missing consensus by 89%.
Continue ReadingShow less
BRIUMVI continued its remarkable commercial run in Q2 2026, with TG Therapeutics posting $240.3 million in revenue — a 70% increase year-over-year and about 5% above the analyst consensus of $229.8 million. The drug's momentum was strong enough that management raised its full-year revenue guidance to $950 million, a signal of sustained confidence in BRIUMVI's market penetration.
The earnings picture told a very different story. Reported EPS came in at just $0.05 against a consensus estimate of $0.44, a miss of roughly 89%. The culprit, per the company, was a sharp ramp-up in research and development spending tied to the development of subcutaneous formulations of BRIUMVI — an investment that consumed cash and overwhelmed the gains from top-line growth.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
The revenue trend over the past several quarters underscores just how fast this franchise has scaled, climbing from $73.5 million in Q2 2024 to $240.3 million in Q2 2026. Whether the R&D spending that pressured Q2 earnings translates into a next-generation product that extends BRIUMVI's competitive life is the central question investors will be watching in the quarters ahead.
Mentioned: TGTX